Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
Gregory G SchwartzMichael SzarekDeepak L BhattVera A BittnerMaja Bujas-BobanovicRafael DiazSergio FazioZlatko FrasShaun G GoodmanRobert A HarringtonJohan Wouter JukemaGaren ManvelianRobert PordyKausik K RayMichel ScemamaHarvey D WhitePh Gabriel Stegnull nullPublished in: European heart journal (2023)
ClinicalTrials.gov NCT01663402.